Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity. The discontinuation is part of portfolio ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback